Minocycline improves cardiac function after myocardial infarction in rats by inhibiting activation of PARP-1 - 31/12/17
, Gang Hong| pagine | 6 |
| Iconografia | 4 |
| Video | 0 |
| Altro | 0 |
Abstract |
To investigate whether Minocycline can protect myocardial cells after myocardial infarction and improve myocardial remodeling through inhibiting PARP-1 activity, thus improving cardiac function. 50 male Wistar rats aged 4 months were used to establish the myocardial infarction model. The experimental rats underwent the echocardiography at 3 d, 14 d and 28 d after operation. After 28 days, the rats were executed and the myocardial tissues in the infarct-related zone were treated with immumohistochemical staining and molecular biology detection. Our study found Minocycline could improve the cardiac function of rats after myocardial infarction. TUNEL results showed that Minocycline could reduce the apoptosis of myocardial cells after myocardial infarction. Western blotting results showed that Minocycline reduced the expressions of apoptotic proteins. Immunohistochemistry and Western blotting showed that Minocycline reduced the expressions of inflammatory factors, NF-κB and IL-1β, etc., in myocardial cells after myocardial infarction. Besides, it was found in further study that Minocycline could inhibit the PARP-1 activity after myocardial ischemic necrosis. In conclusion, Myocardial remodeling occurs after myocardial infarction, affecting the cardiac function. Minocycline can inhibit the activity of apoptosis and inflammatory factors, reduce the apoptosis, alleviate the inflammation and improve the ventricular remodeling through inhibiting PARP-1, thus protecting the cardiac function.
Il testo completo di questo articolo è disponibile in PDF.Keywords : Minocycline, Myocardial infarction, Apoptosis, Inflammatory, PARP-1
Mappa
Vol 97
P. 1119-1124 - gennaio 2018 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?
